Latest News Archives - Page 2 of 3

Hillhurst Biopharmaceuticals Receives Study May Proceed Letter From US FDA to Initiate Phase 1 Clinical Trial of HBI-002

SAN DIEGO, CA (April 23, 2021) Hillhurst Biopharmaceuticals, Inc. ...

Hillhurst Biopharmaceuticals Receives Study May Proceed Letter From US FDA to Initiate Phase 1 Clinical Trial of HBI-002hillhurstbio2021-09-28T02:47:40+00:00

Hillhurst Biopharmaceuticals Receives Funding For Development Of HBI-002 For Treatment of Ulcerative Colitis

SAN DIEGO, CA (March 25, 2021) Hillhurst Biopharmaceuticals, Inc., ...

Hillhurst Biopharmaceuticals Receives Funding For Development Of HBI-002 For Treatment of Ulcerative ColitisCeli Richardson2021-09-23T04:47:45+00:00

Hillhurst biopharmaceuticals receives funding for development of HBI-002 for prevention of anthracyline-related cardiotoxicity in cancer patients

SAN DIEGO, CA (August 19, 2020) Hillhurst Biopharmaceuticals, ...

Hillhurst biopharmaceuticals receives funding for development of HBI-002 for prevention of anthracyline-related cardiotoxicity in cancer patientsMichael Jaramillo2023-09-21T16:56:43+00:00

Hillhurst Biopharmaceuticals Was Selected to Present at NHLBI’s Annual Sickle Cell Disease (SCD) Research Meeting 2020

Hillhurst Biopharmaceuticals Was Selected to Present at NHLBI’s Annual Sickle Cell Disease (SCD) Research Meeting 2020Celi Richardson2021-09-04T22:11:10+00:00

Hillhurst Biopharmaceuticals Receives Phase 2 SBIR Funding For Clinical Development Of HBI-002 For Prevention Of Vaso-Occlusive Crises in Sickle Cell Disease.

SAN DIEGO, CA (Nov. 28, 2018) Hillhurst Biopharmaceuticals, Inc., ...

Hillhurst Biopharmaceuticals Receives Phase 2 SBIR Funding For Clinical Development Of HBI-002 For Prevention Of Vaso-Occlusive Crises in Sickle Cell Disease.Celi Richardson2021-09-04T22:12:21+00:00

Hillhurst Biopharmaceuticals Receives SBIR Funding For Development Of HBI-002 For Prevention Of Delayed Graft Function In Kidney Transplantation

SAN DIEGO, CA (June 14, 2017) Hillhurst Biopharmaceuticals, Inc., ...

Hillhurst Biopharmaceuticals Receives SBIR Funding For Development Of HBI-002 For Prevention Of Delayed Graft Function In Kidney TransplantationCeli Richardson2021-09-04T22:13:22+00:00

Hillhurst Biopharmaceuticals Receives SBIR Funding For Development Of HBI-002 For Prevention Of Vaso-Occlusive Crises In Sickle Cell Disease

SAN DIEGO, CA (May 24, 2016) – Hillhurst Biopharmaceuticals, ...

Hillhurst Biopharmaceuticals Receives SBIR Funding For Development Of HBI-002 For Prevention Of Vaso-Occlusive Crises In Sickle Cell DiseaseCeli Richardson2021-09-04T22:14:42+00:00

Hillhurst Biopharmaceuticals Receives SBIR Funding for Development of HBI-002 as a Cytoprotective Therapeutic in Acute Cerebral Injury

SAN DIEGO, CA (December 1, 2015) – Hillhurst Biopharmaceuticals, ...

Hillhurst Biopharmaceuticals Receives SBIR Funding for Development of HBI-002 as a Cytoprotective Therapeutic in Acute Cerebral InjuryCeli Richardson2021-09-23T05:16:05+00:00

Hillhurst Biopharmaceuticals Was Selected to Presented at the 7th Annual Los Angeles Venture Association (LAVA) First Look LA Conference

Hillhurst Biopharmaceuticals Was Selected to Presented at the 7th Annual Los Angeles Venture Association (LAVA) First Look LA ConferenceCeli Richardson2021-09-09T02:30:57+00:00

Hillhurst Biopharmaceuticals Was Selected to Present Pre-Clinical Research Data at the 9th Annual Foundation for Sickle Cell Disease Research Sickle Cell Disease Research and Educational Symposium

Hillhurst Biopharmaceuticals Was Selected to Present Pre-Clinical Research Data at the 9th Annual Foundation for Sickle Cell Disease Research Sickle Cell Disease Research and Educational SymposiumCeli Richardson2021-09-04T22:18:01+00:00